NCT04459273 2026-02-05FAPI PET RDRCJonsson Comprehensive Cancer CenterPhase 1 Active not recruiting26 enrolled
NCT05400122 2025-11-12Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in CancerCase Comprehensive Cancer CenterPhase 1 Suspended12 enrolled
NCT04500548 2025-09-10Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI StudyNational Cancer Institute (NCI)Phase 1 Withdrawn
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT03082209 2022-12-09A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic MalignanciesAbbViePhase 1 Completed153 enrolled
NCT01183663 2016-06-03Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)M.D. Anderson Cancer CenterPhase 1 Completed180 enrolled